NYSE:HIMSHealthcare
A Look At Hims & Hers Health (HIMS) Valuation After Novo Nordisk Renews Weight Loss Drug Partnership
The sharp recent move in Hims & Hers Health (HIMS) comes after Novo Nordisk agreed to resume selling its weight loss drugs on the platform, ending a public legal dispute and restoring their commercial relationship.
See our latest analysis for Hims & Hers Health.
The renewed Novo Nordisk agreement and the appointment of a new Chief Communications Officer come after a volatile stretch, with a 40.88% 1 month share price return followed by a 37.18% 3 month share price decline and a 36.63% 1 year...